TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT TYPE LIFELINE CURVE 27
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.9 DBMR MARKET POSITION GRID 29
2.10 MARKET END USER COVERAGE GRID 30
2.11 VENDOR SHARE ANALYSIS 31
2.12 SECONDARY SOURCES 32
2.13 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PESTEL ANALYSIS 37
4.2 PORTERS FIVE FORCES MODEL 38
4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO- 39
4.4 INVENTION PATENT- 39
4.5 COUNTRY LEVEL ANALYSIS 40
5 REGULATIONS 42
5.1 DOMINICAN REPUBLIC 44
6 MARKET OVERVIEW 46
6.1 DRIVERS 48
6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER 48
6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER 48
6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION 49
6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING 49
6.2 RESTRAINTS 50
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS 50
6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS 50
6.3 OPPORTUNITIES 51
6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION 51
6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS 51
6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING 51
6.4 CHALLENGES 52
6.4.1 INCREASE IN ABUSE POTENTIAL 52
6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW 53
7 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE 54
7.1 OVERVIEW 55
7.2 ANTIHISTAMINE 56
7.2.1 ANTIHISTAMINE, BY DRUG TYPE 57
7.2.2 LEVOCETIRIZINE 57
7.2.3 CETIRIZINE 58
7.2.4 LORATIDINE 58
7.2.5 DIPHENHYDRAMINE 58
7.2.6 CHLORPHENIRAMINE 59
7.2.7 FEXOFENADINE 59
7.3 CORTICOSTEROIDS 59
7.3.1 FLUTICASONE PROPIONATE 60
7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID 61
7.3.3 CROMOLYN SODIUM 61
7.3.4 OTHERS 61
7.4 DECONGESTANTS 62
7.4.1 DECONGESTANTS, BY DRUG TYPE 63
7.4.2 PSEUDOEPHEDRINE 63
7.4.3 PHENYLEPHRINE 63
7.4.4 OXYMETAZOLINE 64
7.4.5 OTHERS 64
7.5 ANTICHOLINERGICS 64
7.5.1 ANTICHOLINERGICS, BY DRUG TYPE 65
7.5.2 IPRATROPIUM BROMIDE 66
7.5.3 OTHERS 66
7.6 OTHERS 66
8 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS 68
8.1 OVERVIEW 69
8.2 INSTRUMENTS 70
8.2.1 IMMUNO ASSAY ANALYZER 71
8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER 71
8.3 RADIO IMMUNO ASSAY (RIA) 72
8.4 COUNTING IMMUNO ASSAY (CIA) 72
8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA) 72
8.6 FLUOROIMMNOASSAY (FIA) 73
8.7 CHEMILUMINESCENCE ASSAY 73
8.7.1 LUMINOMETERS 74
8.8 REAGENTS AND KITS 74
8.9 OTHERS 75
9 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST 76
9.1 OVERVIEW 77
9.2 IN VIVO TEST 78
9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST 78
9.2.2 SKIN PRICK 79
9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST 79
9.2.2.2 GREER PRICK 79
9.2.3 THE STELLAR POINT 80
9.2.4 PHAZET 80
9.2.5 BIFURCATED SMALLPOX VACCINATION TEST 80
9.2.6 23G INTRAVENOUS NEEDLE 81
9.2.7 OTHERS 81
9.2.8 PATCH TEST 81
9.2.9 INTRADERMAL TEST 82
9.3 IN VITRO TEST 82
9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST 83
9.3.2 SERUM SPECIFIC IGE ASSAY 83
9.3.3 TOTAL IGE ASSAY 83
9.3.4 BASOPHIL ACTIVATION TEST 84
10 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY END USER 85
10.1 OVERVIEW 86
10.2 HOSPITALS 87
10.3 DIAGNOSTICS LABORATORIES 87
10.4 ACADEMIC AND RESEARCH INSTITUTES 88
10.5 OTHERS 89
11 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL 90
11.1 OVERVIEW 91
11.2 DIRECT TENDER 92
11.3 RETAIL SALES 92
11.3.1 RETAIL SALES, BY TYPE 93
11.3.2 HOSPITAL PHARMACY 93
11.3.3 RETAIL PHARMACY 94
11.3.4 ONLINE PHARMACY 94
12 DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE 95
12.1 COMPANY SHARE ANALYSIS: DOMINICAN REPUBLIC SPECIFIC POLLEN ALLERGIES MARKET 95
13 SWOT ANALYSIS 96
14 COMPANY PROFILE 97
14.1 GLAXOSMITHKLINE PLC 97
14.1.1 COMPANY SNAPSHOT 97
14.1.2 REVENUE ANALYSIS 97
14.1.3 PRODUCT PORTFOLIO 98
14.1.4 RECENT DEVELOPMENTS 98
14.2 JOHNSON & JOHNSON SERVICES, INC 99
14.2.1 COMPANY SNAPSHOT 99
14.2.2 REVENUE ANALYSIS 99
14.2.3 PRODUCT PORTFOLIO 100
14.2.4 RECENT DEVELOPMENTS 100
14.3 PERRIGO COMPANY PLC 101
14.3.1 COMPANY SNAPSHOT 101
14.3.2 REVENUE ANALYSIS 101
14.3.3 PRODUCT PORTFOLIO 102
14.3.4 RECENT DEVELOPMENTS 102
14.4 SIEMENS HEALTHCARE GMBH 103
14.4.1 COMPANY SNAPSHOT 103
14.4.2 REVENUE ANALYSIS 103
14.4.3 PRODUCT PORTFOLIO 104
14.4.4 RECENT DEVELOPMENTS 104
14.5 THERMO FISHER SCIENTIFIC INC. 105
14.5.1 COMPANY SNAPSHOT 105
14.5.2 REVENUE ANALYSIS 105
14.5.3 PRODUCT PORTFOLIO 106
14.5.4 RECENT DEVELOPMENT 106
14.6 BAYER AG 107
14.6.1 COMPANY SNAPSHOT 107
14.6.2 REVENUE ANALYSIS 107
14.6.3 PRODUCT PORTFOLIO 108
14.6.4 RECENT DEVELOPMENT 108
14.7 ALCON INC. 109
14.7.1 COMPANY SNAPSHOT 109
14.7.2 REVENUE ANALYSIS 109
14.7.3 PRODUCT PORTFOLIO 110
14.7.4 RECENT DEVELOPMENTS 110
14.8 BIOMRIEUX, SA. 111
14.8.1 COMPANY SNAPSHOT 111
14.8.2 REVENUE ANALYSIS 111
14.8.3 PRODUCT PORTFOLIO 112
14.8.4 RECENT DEVELOPMENTS 112
14.9 CINFA LABORATORIES 113
14.9.1 COMPANY SNAPSHOT 113
14.9.2 PRODUCT PORTFOLIO 113
14.9.3 RECENT DEVELOPMENT 113
14.10 CIRCASSIA 114
14.10.1 COMPANY SNAPSHOT 114
14.10.2 REVENUE ANALYSIS 114
14.10.3 PRODUCT PORTFOLIO 115
14.10.4 RECENT DEVELOPMENTS 115
14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 116
14.11.1 COMPANY SNAPSHOT 116
14.11.2 PRODUCT PORTFOLIO 116
14.11.3 RECENT DEVELOPMENTS 117
14.12 LINCOLN DIAGNOSTICS, INC. 118
14.12.1 COMPANY SNAPSHOT 118
14.12.2 PRODUCT PORTFOLIO 118
14.12.3 RECENT DEVELOPMENTS 118
14.13 MINARIS MEDICAL AMERICA, INC. 119
14.13.1 COMPANY SNAPSHOT 119
14.13.2 PRODUCT PORTFOLIO 119
14.13.3 RECENT DEVELOPMENTS 119
14.14 PRESTIGE CONSUMER HEALTHCARE INC. 120
14.14.1 COMPANY SNAPSHOT 120
14.14.2 REVENUE ANALYSIS 120
14.14.3 PRODUCT PORTFOLIO 121
14.14.4 RECENT DEVELOPMENT 121
14.15 QUEST DIAGNOSTICS INCORPORATED 122
14.15.1 COMPANY SNAPSHOT 122
14.15.2 REVENUE ANALYSIS 122
14.15.3 PRODUCT PORTFOLIO 123
14.15.4 RECENT DEVELOPMENT 123
14.16 SANOFI 124
14.16.1 COMPANY SNAPSHOT 124
14.16.2 REVENUE ANALYSIS 124
14.16.3 PRODUCT PORTFOLIO 125
14.16.4 RECENT DEVELOPMENTS 125
15 QUESTIONNAIRE 126
16 RELATED REPORTS 129

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.